Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Core Insights - Novartis is launching a direct-to-patient (DTP) platform in the US on November 1, 2025, allowing cash-paying patients to purchase Cosentyx at a 55% discount off the list price [1][7] - Cosentyx is Novartis' top-selling product in the US, approved for multiple immune-mediated inflammatory diseases, and has treated over 1.8 million patients globally since its launch in 2015 [1][5] Company Strategy - The DTP platform aims to remove barriers in the healthcare system and provide net prices directly to patients, enhancing affordability [2] - Novartis plans to expand the DTP model to additional medicines in its portfolio and is exploring a direct-to-business model to sell Cosentyx to large employers [2][7] Patient Assistance Programs - Novartis offers various programs to assist patients in accessing Cosentyx, including options for eligible patients with commercial insurance to pay as little as $0 for their prescriptions [3] - The Novartis Patient Assistance Foundation provides Cosentyx at no cost to uninsured patients or those with government insurance who meet specific income guidelines [4] Product Information - Cosentyx (secukinumab) is a fully human biologic that inhibits interleukin-17A, approved for several inflammatory diseases, and supported by extensive clinical data demonstrating long-term safety and efficacy [5] - Since its launch, Cosentyx has been approved in over 100 countries and has a strong real-world data backing its effectiveness [5]